WG
CRBP icon

Winton Group’s Corbus Pharmaceuticals CRBP Stock Holding History

Winton Group’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,558
Closed -$58K – 1383
2020
Q4 		$58K Buy
+1,558
New +$58.2K ﹤0.01% 1284
2019
Q3 		– Sell
-466
Closed -$97K – 1554
2019
Q2 		$97K Buy
+466
New +$99.8K ﹤0.01% 1082

Other funds holding CRBP

EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.32B AUM 31.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Winton Group's CRBP Position: Q1 2021 in Review

Winton Group sold out of Corbus Pharmaceuticals (CRBP) in Q1 2021, closing a stake of 1,558 shares — an estimated $58K sold.

Winton Group first reported a position in CRBP in Q2 2019 and held it in 2 quarters. The position peaked at $97K in Q2 2019. 107 funds tracked by Wall St. Rank hold CRBP as of Q1 2021.

  • Winton Group reported no remaining Corbus Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Winton Group sold 1,558 Corbus Pharmaceuticals shares in Q1 2021, an estimated $58K.
  • Winton Group first reported a position in Corbus Pharmaceuticals in Q2 2019 and held it in 2 quarters.
  • Winton Group's Corbus Pharmaceuticals position peaked at $97K in Q2 2019.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q1 2021.

Based on Winton Group's 13F filing for Q1 2021, filed 21 Jul 2021.